242 related articles for article (PubMed ID: 38481800)
1. Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.
Tripathi P; Kumari R; Pathak R
Int Rev Cell Mol Biol; 2024; 385():1-39. PubMed ID: 38663957
[TBL] [Abstract][Full Text] [Related]
2. PLEKHA7 signaling is necessary for the growth of mutant KRAS driven colorectal cancer.
Jeung HC; Puentes R; Aleshin A; Indarte M; Correa RG; Bankston LA; Layng FIAL; Ahmed Z; Wistuba I; Yao Y; Duenas DG; Zhang S; Meuillet EJ; Marassi F; Liddington RC; Kirkpatrick L; Powis G
Exp Cell Res; 2021 Dec; 409(2):112930. PubMed ID: 34800542
[TBL] [Abstract][Full Text] [Related]
3. Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy.
Wolpaw AJ; Dang CV
Trends Cell Biol; 2018 Mar; 28(3):201-212. PubMed ID: 29229182
[TBL] [Abstract][Full Text] [Related]
4. Impact of KRAS mutation on the tumor microenvironment in colorectal cancer.
Zhou Y; Kuang Y; Wang C; Yu Y; Pan L; Hu X
Int J Biol Sci; 2024; 20(5):1947-1964. PubMed ID: 38481800
[TBL] [Abstract][Full Text] [Related]
5. Impact of RAS mutations on the immune infiltrate of colorectal liver metastases: A preliminary study.
Polidoro MA; Milana F; Soldani C; Franceschini B; Anselmo A; Colombo FS; Di Tommaso L; Cimino M; Carnevale S; Lleo A; Jaillon S; Torzilli G; Donadon M
J Leukoc Biol; 2020 Aug; 108(2):715-721. PubMed ID: 32108374
[TBL] [Abstract][Full Text] [Related]
6. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy.
Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
J Cell Physiol; 2019 May; 234(5):5601-5612. PubMed ID: 30341899
[TBL] [Abstract][Full Text] [Related]
7. The current understanding on the impact of KRAS on colorectal cancer.
Meng M; Zhong K; Jiang T; Liu Z; Kwan HY; Su T
Biomed Pharmacother; 2021 Aug; 140():111717. PubMed ID: 34044280
[TBL] [Abstract][Full Text] [Related]
8. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.
Lee J; Jain A; Kim P; Lee T; Kuller A; Princen F; In-GuDo ; Kim SH; Park JO; Park YS; Singh S; Kim HC
PLoS One; 2014; 9(8):e103551. PubMed ID: 25090459
[TBL] [Abstract][Full Text] [Related]
9. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
10. Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.
Mausey N; Halford Z
Ann Pharmacother; 2024 Jun; 58(6):622-635. PubMed ID: 37700573
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive profiling of enhancer RNA in stage II/III colorectal cancer defines two prognostic subtypes with implications for immunotherapy.
Bu X; Liu S; Zhang Z; Wu J; Pan S; Hu Y
Clin Transl Oncol; 2024 Apr; 26(4):891-904. PubMed ID: 37697139
[TBL] [Abstract][Full Text] [Related]
12. DNMT1 expression partially dictates 5-Azacytidine sensitivity and correlates with RAS/MEK/ERK activity in gastric cancer cells.
Chen Z; Zhang L; Yang Y; Liu H; Kang X; Nie Y; Fan D
Epigenetics; 2023 Dec; 18(1):2254976. PubMed ID: 37691391
[TBL] [Abstract][Full Text] [Related]
13. CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.
Miao B; Hu Z; Mezzadra R; Hoeijmakers L; Fauster A; Du S; Yang Z; Sator-Schmitt M; Engel H; Li X; Broderick C; Jin G; Gomez-Eerland R; Rozeman L; Lei X; Matsuo H; Yang C; Hofland I; Peters D; Broeks A; Laport E; Fitz A; Zhao X; Mahmoud MAA; Ma X; Sander S; Liu HK; Cui G; Gan Y; Wu W; Xiao Y; Heck AJR; Guan W; Lowe SW; Horlings HM; Wang C; Brummelkamp TR; Blank CU; Schumacher TNM; Sun C
Cancer Cell; 2023 Oct; 41(10):1817-1828.e9. PubMed ID: 37683639
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]